

Supporting Information

Human Cytotoxicity, Hemolytic Activity, Anti-Inflammatory Activity and Aqueous Solubility of Ibuprofen-based Ionic Liquids

Joana C. Bastos ¹, Nicole S. M. Vieira ¹, Maria Manuela Gaspar ², Ana B. Pereiro ¹ and João M. M. Araújo ^{1,*}

¹ LAQV, REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal


² Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal

* Correspondence: jmmda@fct.unl.pt; Tel.: +351-212948300

Characterization of the Ibuprofen-based Ionic Liquids

The prepared ibuprofen-based ionic liquids, ibuprofen and ibuprofen sodium salt were completely characterized by ^1H and ^{13}C NMR in order to check their expected structures. Additionally, the quantitative integration of their characteristic ^1H NMR resonance peaks unfold the expected cation/anion correlations. Also, there were no peaks assigned to impurities in the ^1H NMR spectra.

Ibuprofen




^1H NMR (400 MHz, D₂O): $\delta/\text{ppm} = 7.20$ (d, $J = 8.0$ Hz, 2H, 6), 7.15 (d, $J = 8.3$ Hz, 2H, 5), 3.58 (m, 1H, 2), 2.40 (d, $J = 7.1$ Hz, 2H, 8), 1.75 (dd, $J = 13.5, 6.6$ Hz, 1H, 9), 1.33 (d, $J = 7.2$ Hz, 3H, 3), 0.79 (d, $J = 6.6$ Hz, 6H, 10).

^1H NMR (400 MHz, DMSO): $\delta/\text{ppm} = \delta$ 12.25 (s, 1H, OH), 7.19 (d, $J = 7.9$ Hz, 2H, 6), 7.11 (d, $J = 7.9$ Hz, 2H, 5), 3.63 (q, $J = 7.1$ Hz, 1H, 2), 2.42 (d, $J = 7.1$ Hz, 2H, 8), 1.81 (dp, $J = 13.5, 6.9$ Hz, 1H, 9), 1.35 (d, $J = 7.1$ Hz, 3H, 3), 0.86 (d, $J = 6.6$ Hz, 6H, 10). ^{13}C NMR (101 MHz, DMSO): $\delta/\text{ppm} = 175.95$ (s, 1), 140.02 (s, 7), 138.94 (s, 4), 129.43 (s, 6), 127.57 (s, 5), 44.74 (s, 8), 44.68 (s, 2), 30.03 (d, $J = 8.9$ Hz, 9), 22.42 (d, $J = 43.1$ Hz, 10), 18.91 (d, $J = 16.1$ Hz, 3).

^1H NMR (400 MHz, CDCl₃): $\delta/\text{ppm} = \delta$ 7.25 (d, $J = 7.8$ Hz, 2H, 6), 7.13 (d, $J = 7.8$ Hz, 2H, 5), 3.74 (q, $J = 7.1$ Hz, 1H, 2), 2.48 (d, $J = 7.1$ Hz, 2H, 8), 1.87 (tt, $J = 13.4, 6.7$ Hz, 1H, 9), 1.52 (s, 3H, 3), 0.93 (d, $J = 6.6$ Hz, 6H, 10). ^{13}C NMR (101 MHz, CDCl₃): $\delta/\text{ppm} = 180.61$ (s, 1), 140.87 (s, 7), 137.00 (s, 4), 129.40 (s, 6), 127.29 (s, 5), 45.05 (s, 8), 44.94 (s, 2), 30.17 (s, 9), 22.40 (s, 10), 18.11 (s, 3).

Sodium Ibuprofen




^1H NMR (500 MHz, D₂O): $\delta/\text{ppm} = 7.19$ (d, $J = 8.0$ Hz, 2H, 6), 7.13 (d, $J = 7.9$ Hz, 2H, 5), 3.53 (q, $J = 7.1$ Hz, 1H, 2), 2.40 (d, $J = 7.1$ Hz, 2H, 8), 1.82–1.69 (m, 1H, 9), 1.31 (d, $J = 7.2$ Hz, 3H, 3), 0.79 (d, $J = 6.6$ Hz, 6H, 10). ^{13}C NMR (126 MHz, D₂O): $\delta/\text{ppm} = 183.98$ (d, $J = 3.0$ Hz, 1), 140.67 (s, 7), 140.44 (s, 4), 129.41 (s, 6), 127.10 (s, 5), 48.12 (d, $J = 3.9$ Hz, 8), 44.15 (d, $J = 3.9$ Hz, 2), 29.68 (s, 9), 21.56 (s, 10), 18.41 (s, 3).

^1H NMR (500 MHz, DMSO): $\delta/\text{ppm} = 7.17$ (d, $J = 8.0$ Hz, 2H, 6), 6.96 (d, $J = 8.0$ Hz, 2H, 5), 3.21 (q, $J = 7.1$ Hz, 1H, 2), 2.37 (d, $J = 7.1$ Hz, 2H, 8), 1.87–1.70 (m, 1H, 9), 1.22 (t, $J = 8.2$ Hz, 3H, 3), 0.86 (d, $J = 6.6$ Hz, 6H, 10). ^{13}C NMR (101 MHz, DMSO): $\delta/\text{ppm} = 177.55$ (s, 1), 143.79 (s, 7), 137.88 (s, 4), 128.48 (s, 6), 127.68 (s, 5), 49.04 (s, 8), 44.84 (s, 2), 30.19 (s, 9), 22.69 (s, 10), 20.74 (s, 3).

^1H NMR (400 MHz, CDCl₃): $\delta/\text{ppm} = 7.24$ (d, $J = 8.0$ Hz, 2H, 6), 7.12 (d, $J = 8.0$ Hz, 2H, 5), 3.74 (q, $J = 7.0$ Hz, 1H, 2), 2.47 (d, $J = 7.2$ Hz, 2H, 8), 1.94–1.75 (m, 1H, 9), 1.52 (d, $J = 7.2$ Hz, 3H, 3), 0.92 (d, $J = 6.6$ Hz, 6H, 10). ^{13}C NMR (101 MHz, CDCl₃): $\delta/\text{ppm} = 179.40$ –176.46

(m, 1), 142.58 – 138.96 (m, 7), 137.83 – 135.65 (m, 4), 129.42 (s, 6), 127.25 (s, 5), 45.04 (s, 8), 44.74 – 44.31 (m, 2), 30.16 (s, 9), 22.38 (s, 10), 18.20 (s, 3).


1-Ethyl-3-methylimidazolium ibuprofenate ([C₂C₁Im][Ibu])



¹H NMR (400 MHz, D₂O): δ/ppm = 8.58 (s, 1H, 2'), 7.37 (s, 1H, 4'), 7.30 (s, 1H, 5'), 7.18 (d, J = 7.9 Hz, 2H, 6), 7.12 (d, J = 7.9 Hz, 2H, 5), 4.11 (q, J = 7.4 Hz, 2H, 7'), 3.77 (s, 3H, 6'), 3.53 (m, 1H, 2), 2.38 (d, J = 7.1 Hz, 2H, 8), 1.74 (dp, J = 13.5, 6.7 Hz, 1H, 9), 1.39 (t, J = 7.4 Hz, 3H, 8'), 1.30 (d, J = 7.2 Hz, 3H, 3), 0.78 (d, J = 6.6 Hz, 6H, 10). ¹³C NMR (101 MHz, DMSO): δ/ppm = 183.92 (s, 1), 140.71 (s, 7), 140.42 (s, 4), 129.40 (s, 6), 127.12 (s, 5), 123.36 (s, 4'), 121.78 (s, 5'), 48.18 (s, 7'), 44.70 (s, 8), 44.17 (s, 2), 35.49 (s, 6'), 29.69 (s, 9), 21.58 (s, 10), 18.43 (s, 3), 14.40 (s, 8').


¹H NMR (400 MHz, DMSO): δ/ppm = 9.48 (s, 1H, 2'), 7.79 (s, 1H, 4'), 7.70 (s, 1H, 5'), 7.14 (d, J = 7.8 Hz, 2H, 5), 6.94 (d, J = 7.8 Hz, 2H, 6), 4.18 (q, J = 7.3 Hz, 2H, 7'), 3.84 (s, 3H, 6'), 3.15 (q, J = 7.1 Hz, 1H, 2), 2.37 (d, J = 7.1 Hz, 2H, 8), 1.78 (dp, J = 13.3, 6.8 Hz, 1H, 9), 1.40 (t, J = 7.3 Hz, 3H, 8'), 1.19 (d, J = 7.1 Hz, 3H, 3), 0.86 (d, J = 6.6 Hz, 6H, 10). ¹³C NMR (101 MHz, DMSO): δ/ppm = 175.76 (s, 1), 144.45 (s, 2'), 137.55 (s, 7), 137.27 (s, 4), 128.35 (s, 6), 127.64 (s, 5), 123.97 (s, 4'), 122.38 (s, 5'), 49.65 (s, 7'), 44.86 (s, 8), 44.50 (s, 2), 36.06 (s, 6'), 30.19 (s, 9), 22.69 (s, 10), 20.86 (s, 3), 15.60 (s, 8').

1-(2-Hydroxyethyl)-3-methylimidazolium ibuprofenate ([C_{2(OH)}C₁Im][Ibu])



¹H NMR (500 MHz, D₂O): δ/ppm = 7.41 (d, J = 1.9 Hz, 1H, 4'), 7.36 (d, J = 1.8 Hz, 1H, 5'), 7.18 (dd, J = 4.7, 3.2 Hz, 2H, 6), 7.12 (dd, J = 4.9, 3.0 Hz, 2H, 5), 4.26 – 4.19 (m, 2H, 7'), 3.88 – 3.78 (m, 5H, 6', 8'), 3.51 (m, 1H, 2), 2.39 (dd, J = 6.9, 3.5 Hz, 2H, 8), 1.75 (ddd, J = 20.1, 10.1, 4.9 Hz, 1H, 9), 1.30 (dd, J = 7.1, 3.6 Hz, 3H, 3), 0.91 – 0.68 (m, 6H, 10). ¹³C NMR (126 MHz, D₂O): δ/ppm = 183.97 (s, 2'), 140.68 (s, 7), 140.44 (s, 4), 129.39 (s, 6), 127.09 (s, 5), 123.52 (s, 4'), 122.35 (s, 5'), 59.70 (s, 7'), 51.45 (s, 8), 48.15 (s, 2), 44.15 (s, 8'), 35.61 (s, 6'), 29.67 (s, 9), 21.55 (s, 10), 18.40 (s, 3).

¹H NMR (400 MHz, DMSO): δ/ppm = 9.31 (s, 1H, 2'), 7.73 (s, 1H, 4'), 7.67 (s, 1H, 5'), 7.15 (d, J = 7.8 Hz, 2H, 6), 6.96 (d, J = 7.8 Hz, 2H, 5), 4.21 (t, J = 4.9 Hz, 2H, 7'), 3.83 (s, 3H, 6'), 3.69 (dd, J = 13.8, 8.9 Hz, 2H, 8'), 3.18 (q, J = 7.1 Hz, 1H, 2), 2.36 (t, J = 8.1 Hz, 2H, 8), 1.87 – 1.68 (m, 1H, 9), 1.19 (d, J = 7.1 Hz, 3H, 3), 0.85 (d, J = 6.6 Hz, 6H, 10). ¹³C NMR (101 MHz, DMSO): δ/ppm = 176.29 (s, 1), 144.09 (s, 2'), 137.75 (s, 7), 137.62 (s, 4), 128.45 (s, 6), 127.64 (s, 5), 123.62 (s, 4'), 123.14 (s, 5'), 59.66 (s, 7'), 52.02 (s, 8), 49.39 (s, 2), 44.84 (s, 8'), 36.05 (s, 6'), 30.20 (s, 9), 22.70 (s, 10), 20.77 (s, 3).

Cholinium ibuprofenate ([N_{1112(OH)}][Ibu])


¹H NMR (500 MHz, D₂O): δ/ppm = 7.19 (d, *J* = 8.1 Hz, 2H, 6), 7.13 (d, *J* = 8.0 Hz, 2H, 5), 4.01 – 3.91 (m, 2H, 5'), 3.60 – 3.46 (m, 1H, 2), 3.46 – 3.36 (m, 2H, 4'), 3.10 (s, 9H, 1',2',3'), 2.40 (d, *J* = 7.1 Hz, 2H, 8), 1.82 – 1.67 (m, 1H, 9), 1.30 (d, *J* = 7.2 Hz, 3H, 3), 0.79 (d, *J* = 6.6 Hz, 6H, 10). ¹³C NMR (126 MHz, D₂O) : δ/ppm = 183.96 (s, 1), 140.69 (s, 7), 140.43 (s, 4), 129.41 (s, 6), 127.10 (s, 5), 68.57 – 65.25 (m, 5'), 55.55 (s, 4'), 54.66 – 53.28 (m, 1', 2', 3'), 48.15 (s, 8), 44.15 (s, 2), 29.68 (s, 9), 21.56 (s, 10), 18.41 (s, 3).

¹H NMR (500 MHz, DMSO): δ/ppm = 7.15 (d, *J* = 8.0 Hz, 2H, 5), 6.96 (d, *J* = 8.0 Hz, 2H, 6), 3.90 – 3.73 (m, 2H, 5'), 3.18 (q, *J* = 7.1 Hz, 1H, 2), 3.09 (s, 9H, 1', 2', 3'), 2.37 (d, *J* = 7.1 Hz, 2H, 8), 1.77 (dq, *J* = 20.1, 6.7 Hz, 1H, 9), 1.20 (d, *J* = 7.1 Hz, 3H, 3), 0.86 (d, *J* = 6.6 Hz, 6H, 10). ¹³C NMR (126 MHz, DMSO) : δ/ppm = 176.34 (s, 1), 144.07 (s, 7), 137.77 (s, 4), 128.46 (s, 6), 127.64 (s, 5), 67.68 (s, 5'), 55.43 (s, 4'), 54.01 – 53.24 (m, 1', 2', 3'), 49.35 (s, 8), 44.84 (s, 2), 30.19 (s, 9), 22.70 (s, 10), 20.79 (s, 3).

Figure S1. DSC profile and analysis with TA Instruments Universal Analysis V4.5A software at $1^{\circ}\text{C}/\text{min}$ of ibuprofen.




Figure S2. DSC profile and analysis with TA Instruments Universal Analysis V4.5A software at $1^{\circ}\text{C}/\text{min}$ of $[\text{C}_2\text{ClIm}][\text{Ibu}]$.




Figure S3. DSC profile and analysis with TA Instruments Universal Analysis V4.5A software at 1°C/min of $[C_{2(OH)}C_1Im][Ibu]$.




Figure S4. DSC profile and analysis with TA Instruments Universal Analysis V4.5A software at 1°C/min of $[N_{1112(OH)}][Ibu]$.




Table S1. Chemical shifts for the hydrogens in the position 2 and 3 (as depicted chemical structure of ibuprofen on the right) for ibuprofen, sodium ibuprofen and API-ILs in D₂O.

Compounds	H2 (δ/ppm)	H3 (δ/ppm)
Ibuprofen	3.58	1.33
Na[ibu]	3.53	1.31
[C ₂ C ₁ Im][ibu]	3.53	1.30
[C ₂ (OH)C ₁ Im][ibu]	3.51	1.30
[N _{1112(OH)}][ibu]	3.53	1.30




Figure S5. Non-linear regression fitting curves, calculated Log EC₅₀ ± standard deviation and respective R-squared and p-value for ibuprofen (**A**), [C₂C₁Im][Ibu] (**B**), [C_{2(OH)C₁Im][Ibu] (**C**), [N_{1112(OH)}][Ibu] (**D**), [C₂C₁Im]Cl (**E**), [C_{2(OH)C₁Im]Cl (**F**) and [N_{1112(OH)}]Cl (**G**) in Caco-2 cell line.}}




Figure S6. EC₅₀ values of ibuprofen, ibuprofen-based ILs and IL/salt cation “suppliers” for the API-ILs ([C₂C₁Im]Cl, [C_{2(OH)}C₁Im]Cl, [N_{1112(OH)}]Cl) in Caco-2 cell line exposed to the compounds for 24h. The R-squared was greater than 0.9540 an P < 0.0001 for all fitted curves.




Table S2. Inhibition of BSA denaturation in PBS pH 7.4 at different concentrations for the neutral and salt form of ibuprofen and API-ILs. The presented value is the mean of at least two independent measures \pm standard deviation.

Concentration (mM)	Inhibition of BSA denaturation (%)	Concentration (mM)	Inhibition of BSA denaturation (%)
Ibuprofen		Sodium Ibuprofen	
0.727	19.93 \pm 2.00	0.657	20.15 \pm 1.10
1.697	42.85 \pm 1.97	1.533	36.97 \pm 1.61
2.424	67.66 \pm 2.49	2.190	61.24 \pm 4.24
3.636	76.40 \pm 1.32	3.286	69.54 \pm 4.81
4.848	74.34 \pm 1.32		
[C₂C₁Im][Ibu]		[C_{2(OH)C₁Im][Ibu]}	
0.474	23.30 \pm 1.15	0.451	43.67 \pm 3.21
1.106	48.77 \pm 2.52	1.053	70.99 \pm 3.81
1.580	55.56 \pm 2.73	1.504	82.25 \pm 0.44
2.370	63.27 \pm 2.08	2.256	86.27 \pm 0.95
[N_{1112(OH)Im][Ibu]}			
0.485	31.79 \pm 1.57		
1.131	39.66 \pm 1.33		
1.616	50.93 \pm 2.00		
2.424	59.41 \pm 0.79		